Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.

Mohamed Ismail Abdul Aziz,Ling Eng Tan,Wan Hui Gloria Tan,Chee Keong Toh,Lydia Pui Yee Loke,Fiona Pearce,Kwong Ng

Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.

2020

Mohamed Ismail Abdul Aziz
Ling Eng Tan
Wan Hui Gloria Tan
Chee Keong Toh
Lydia Pui Yee Loke
Fiona Pearce
Kwong Ng

Objective: To assess the cost-effectiveness of pembrolizumab monotherapy compared with standard chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in previously untreated...

Keywords:

Cost-effectiveness analysis
Intensive care medicine
Oncology
Lung cancer
non small cell
Chemotherapy
PD-L1
Internal medicine
Pembrolizumab
Medicine
Programmed Cell Death 1 Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations